Géraldine Gebhart

Dienst : Nucleaire geneeskunde

geraldine.gebhart [at] bordet.be

Publicaties

Chemotherapy de-escalation using an <sup>18</sup>F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial.

Auteurs : Pérez-García JM, Gebhart G, Ruiz Borrego M, Stradella A, Bermejo B, Schmid P, Marmé F, Escrivá-de-Romani S, Calvo L, Ribelles N, Martinez N, Albacar C, Prat A, Dalenc F, Kerrou K, Colleoni M, Afonso N, Di Cosimo S, Sampayo-Cordero M, Malfettone A, Cortés J, Llombart-Cussac A
Jaar : 2021
Journal : Lancet Oncol

Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer.

Auteurs : Hunter FW, Barker HR, Lipert B, Rothé F, Gebhart G, Piccart-Gebhart M, Sotiriou C, Jamieson SMF
Jaar : 2020
Journal : Br J Cancer

Added value of para-aortic surgical staging compared to <sup>18</sup>F-FDG PET/CT on the external beam radiation field for patients with locally advanced cervical cancer: An ONCO-GF study.

Auteurs : De Cuypere M, Lovinfosse P, Goffin F, Gennigens C, Rovira R, Duch J, Fastrez M, Gebhart G, Squifflet JL, Luyckx M, Charaf G, Crener K, Buxant F, Bucella D, Jouret M, Hustinx R, Kridelka F
Jaar : 2020
Journal : Eur J Surg Oncol

How COVID-19 pandemic affected cancer progression: Three different scenarios evidenced by PET imaging.

Auteurs : Mileva M, Artigas C, Gebhart G, Flamen P, Karfis I
Jaar : 2020
Journal : Hell J Nucl Med

Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle.

Auteurs : Bartelink IH, Jones EF, Shahidi-Latham SK, Lee PRE, Zheng Y, Vicini P, van t Veer L, Wolf D, Iagaru A, Kroetz DL, Prideaux B, Cilliers C, Thurber GM, Wimana Z, Gebhart G
Jaar : 2019
Journal : Clin Pharmacol Ther

Meer publicaties »

Géraldine Gebhart

Volg ons!

De gezondheidscrisis : een goede aanleiding om te stoppen met roken !

Talen

Contact